Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$7.22
-1.5%
$6.73
$4.66
$7.86
$120.40M0.657,061 shs9,255 shs
Genelux Corporation stock logo
GNLX
Genelux
$3.44
-0.6%
$2.74
$1.60
$5.89
$130.56M-0.34173,436 shs121,328 shs
Passage Bio, Inc. stock logo
PASG
Passage Bio
$0.40
-9.9%
$0.38
$0.26
$1.33
$27.41M1.67383,191 shs1.26 million shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.12
-3.1%
$3.15
$1.60
$10.48
$124.23M1.35798,023 shs138,521 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
+2.66%+7.48%+5.01%+32.07%+732,999,900.00%
Genelux Corporation stock logo
GNLX
Genelux
-0.57%+21.83%+27.68%+47.86%+59.45%
Passage Bio, Inc. stock logo
PASG
Passage Bio
+8.62%+8.54%-4.40%+21.86%-48.42%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
+6.27%+15.83%-1.53%-14.13%+51.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
1.7931 of 5 stars
3.62.00.00.02.60.00.0
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.8117 of 5 stars
3.53.00.00.01.11.71.3
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
1.2063 of 5 stars
3.61.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
3.00
Buy$13.6789.29% Upside
Genelux Corporation stock logo
GNLX
Genelux
3.20
Buy$17.75415.99% Upside
Passage Bio, Inc. stock logo
PASG
Passage Bio
3.00
Buy$7.501,786.79% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50557.05% Upside

Current Analyst Ratings Breakdown

Latest PASG, BHST, GNLX, and TARA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/8/2025
Genelux Corporation stock logo
GNLX
Genelux
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSpeculative Buy ➝ Speculative Buy$25.00 ➝ $23.00
5/5/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$27.70M4.28N/AN/A$0.08 per share90.25
Genelux Corporation stock logo
GNLX
Genelux
$10K12,982.56N/AN/A$0.76 per share4.53
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$0.99 per shareN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$4.77 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)
Genelux Corporation stock logo
GNLX
Genelux
-$29.87M-$0.88N/AN/AN/AN/A-93.04%-74.17%8/13/2025 (Estimated)
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$64.77M-$1.02N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)

Latest PASG, BHST, GNLX, and TARA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.43N/AN/AN/AN/AN/A
5/15/2025Q1 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million
5/13/2025Q1 2025
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/8/2025Q1 2025
Genelux Corporation stock logo
GNLX
Genelux
-$0.24-$0.21+$0.03-$0.21N/AN/A
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
0.51
0.30
Genelux Corporation stock logo
GNLX
Genelux
N/A
4.67
4.67
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
3.74
3.74
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
18.03
18.03

Institutional Ownership

CompanyInstitutional Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Genelux Corporation stock logo
GNLX
Genelux
37.33%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%

Insider Ownership

CompanyInsider Ownership
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
Genelux Corporation stock logo
GNLX
Genelux
9.30%
Passage Bio, Inc. stock logo
PASG
Passage Bio
5.00%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A16.43 millionN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
1037.74 million34.23 millionNot Optionable
Passage Bio, Inc. stock logo
PASG
Passage Bio
13062.15 million59.04 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million35.34 millionOptionable

Recent News About These Companies

Protara Therapeutics, Inc. (TARA) - Yahoo Finance
Analysts Set Expectations for TARA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioHarvest Sciences stock logo

BioHarvest Sciences NASDAQ:BHST

$7.22 -0.11 (-1.50%)
As of 03:59 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Genelux stock logo

Genelux NASDAQ:GNLX

$3.44 -0.02 (-0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$3.40 -0.04 (-1.16%)
As of 06:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$0.40 -0.04 (-9.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 0.00 (-1.13%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.12 -0.10 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$3.10 -0.02 (-0.64%)
As of 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.